Triple-Negative Breast Cancer

Researchers suggested that these findings support using minimal residual disease as a major stratification variable in all clinical trials to be conducted in patients with triple negative breast cancer.

The phase 3 ASCENT trial designed to evaluate sacituzumab govitecan-hziy in patients with brain metastasis-negative, metastatic triple-negative breast cancer met its primary end point of progression-free survival.

The combination demonstrated a statistically significant and clinically meaningful improvement in pathological complete response for the treatment of individuals with early triple-negative breast cancer, regardless of PD-L1 expression.